Showing 4601-4610 of 5771 results for "".
- Eli Lilly Starts Late-Stage Study of Neutralizing Antibody Against SARS-CoV-2 in Nursing Homeshttps://modernod.com/news/eli-lilly-starts-late-stage-study-of-neutralizing-antibody-against-sars-cov-2-in-nursing-homes/2478118/Eli Lilly announced the initiation of a phase 3 study investigating whether its antibody-based drug LY-CoV555 can help reduce the rate of SARS-CoV-2 infection and COVID-19 in long-term care facilities in the US. The company is developing the neutralizing IgG1 antibody, which
- Vision Expo Introduces InFocus Video Serieshttps://modernod.com/news/vision-expo-introduces-infocus-video-series/2478114/Vision Expo announced the launch of InFocus, a series of 4-minute video interviews with some of Vision Expo’s top industry attendees and OPTImum program buyers conducted by Suzanne Krauss, OPTImum Program Manager at Vision Expo. The InFocus Series launches this week with a new video to be
- Sanofi, GSK Gain $2.1 Billion From US Government for Development, Supply of COVID-19 Vaccinehttps://modernod.com/news/sanofi-gsk-gain-2-1-billion-from-us-government-for-development-supply-of-covid-19-vaccine/2478107/Sanofi and GlaxoSmithKline announced that the US government will provide more than $2.1 billion to support further development, manufacturing and delivery of initial doses of the companies’ adjuvanted vaccine against COVID-19. The vaccine candidate is based on Sanofi’s recombinant pro
- Oxurion Appoints Grace Chang, MD, PhD, as Chief Medical Officerhttps://modernod.com/news/oxurion-appoints-grace-chang-md-phd-as-chief-medical-officer/2478109/Oxurion NV announced the appointment of Grace Chang, MD, PhD, as the company’s Chief Medical Officer, effective August 1, 2020. Dr. Chang is a board-certified ophthalmologist and practicing vitreoretinal surgeon with deep expertise in ophthalmic drug research and development. She will be r
- AAO: ACA’s Medicaid Expansion Failed to Improve Diabetic Dilated Eye Exam Rates Long-Termhttps://modernod.com/news/aao-acas-medicaid-expansion-failed-to-improve-diabetic-dilated-eye-exam-rates-long-term/2478111/New research shows significantly more people with diabetes got their critical annual dilated eye exam during the first 2 years following Medicaid expansion under the under the Affordable Care Act (ACA). However, this encouraging increase in the exam rate did not persist beyond 2 years. The study’
- ReFocus Eye Health Acquires OptiCare Eye Health & Vision Centershttps://modernod.com/news/refocus-eye-health-acquires-opticare-eye-health-vision-centers/2478105/ReFocus Eye Health has announced the acquisition of OptiCare Eye Health & Vision Centers. Terms of the deal were not disclosed. “We couldn’t be more excited about the surgeons and staff of OptiCare becoming part of the ReFocus family,”
- iOR Partners Welcomes Tom Frinzi to their Boardhttps://modernod.com/news/ior-partners-welcomes-tom-frinzi-to-their-board/2478104/iOR Partners, a provider of office-based surgery in ophthalmology, announced that industry veteran Tom Frinzi has joined their Board of Directors. “We are thrilled that Tom Frinzi is joining our Board. He bring
- New Topline Tepezza Data Underscore its Efficacy in Potential for Retreatment in People Living with Thyroid Eye Disease (TED)https://modernod.com/news/new-topline-tepezza-data-underscore-its-efficacy-in-potential-for-retreatment-in-people-living-with-thyroid-eye-disease-ted/2478101/Horizon Therapeutics announced positive topline data from two clinical trials that add to the growing body of evidence supporting the efficacy and safety of Tepezza (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED). Tepezza is the first and only medicine approved by the FDA for t
- Kubota Vision Demonstrates 3D Imaging Capabilities Using AI on PBOShttps://modernod.com/news/kubota-vision-demonstrates-3d-imaging-capabilities-using-ai-on-pbos/2478095/Kubota Vision announced that the company demonstrated 3D imaging capabilities using artificial intelligence (AI) on its Patient Based Ophthalmology Suite (PBOS) in-home optical coherence tomography (OCT) device.1 Kubota Vision completed a successful clinical study in October 201
- MicroOptx Completes Patient Enrollment in Initial Phase of US Pivotal Trial for the Beacon Aqueous Microshunthttps://modernod.com/news/microoptx-completes-patient-enrollment-in-initial-phase-of-us-pivotal-trial-for-the-beacon-aqueous-microshunt/2478098/MicroOptx announced the completion of enrollment in the initial phase of the Beacon Study. This is the FDA investigational device exemption (IDE) clinical trial of the Beacon Aqueous Microshunt. Study participants treated during the initial phase of the interventional, single-arm, open label, mul